Latest Breaking News On - Hummingbird bio - Page 1 : comparemela.com

Synaffix to provide Hummingbird Bioscience access to proprietary ADC technologies Synaffix to receive up to $150m in upfront and milestone payments plus royalties SAN FRANCISCO, HOUSTON and SINGAPORE, Jan. 4, 2023 /PRNewswire/ Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, and Hummingbird Bioscience (Hummingbird Bio), a data-driven precision biotherapeutics company using its Rational Antibody Discovery (RAD) platform to discover and engineer antibodies against optimal yet elusive epitopes, thereby unlocking novel mechanisms of action, today announced that they entered into a licensing agreement that will enable Hummingbird Bio to develop a next generation ADC program using Synaffix technology. Under the terms of the agreement, Synaffix will be eligible to receive up to $150 million, including upfront and milestone payments,

United statesInnovent biologicsPlatform technologyHummingbird bioscienceHummingbird bioRational antibody discoveryChief executive officerPiers ingramMersana therapeuticsShanghai miracogenKyowa kirinBiogeneration venturesSynaffix to provide hummingbird bioscience access proprietary adc technologies receive up 150m in upfront and milestone payments plus royalties san franciscoOuston and singaporeJan 4023 prnewswire synaffixbv synaffix